Robert Camp, PhD, MD
Associate Research Scientist in PathologyDownloadHi-Res Photo
Cards
Appointments
Pathology
Primary
Contact Info
About
Titles
Associate Research Scientist in Pathology
Biography
My primary activities involve teaching residents, medical and PA students at Yale School of Medicine, with an emphasis on curriculum development and the application of new technologies for instruction.
Appointments
Pathology
Associate Research ScientistPrimary
Other Departments & Organizations
Education & Training
- Resident
- Yale-New Haven Hospital (2000)
- MD
- Yale University School of Medicine (1997)
- PhD
- Yale University School of Medicine, Immunology (1992)
- BA
- Swarthmore College, Biology (1987)
Board Certifications
Pathology Anatomic
- Certification Organization
- AB of Pathology
- Original Certification Date
- 2001
Research
Overview
In addition to developing methods for the quantitative analysis of biomarkers of tissue sessions, I have developed a number of algorithms and programs for quantifying and statistically analyzing biomarker expression. These include the AQUA (Automated Quantitative Analysis) System (US Patents 7219016, 7873480, 8036833, 8121794), as well X-Tile a graphical method for the identification of tumor subpopulations.
Medical Subject Headings (MeSH)
Automation, Laboratory; Biomarkers; Data Interpretation, Statistical
- View Lab Website
Yale Tissue Microarray Facility
Research at a Glance
Yale Co-Authors
Frequent collaborators of Robert Camp's published research.
Publications Timeline
A big-picture view of Robert Camp's research output by year.
Research Interests
Research topics Robert Camp is interested in exploring.
David Rimm, MD, PhD
Harriet Kluger, MD
Lucia Jilaveanu, MD, PhD
Malini Harigopal, MD
Barbara Burtness, MD
Mario Sznol, MD
140Publications
13,383Citations
Biomarkers
Data Interpretation, Statistical
Publications
2021
Reliability of histopathologic diagnosis of fibrotic interstitial lung disease: an international collaborative standardization project
Camp R, Smith ML, Larsen BT, Roden AC, Farver C, Moreira AL, Attanoos R, Pillappa R, Sansano I, Fabro AT, Homer RJ. Reliability of histopathologic diagnosis of fibrotic interstitial lung disease: an international collaborative standardization project. BMC Pulmonary Medicine 2021, 21: 184. PMID: 34074264, PMCID: PMC8170950, DOI: 10.1186/s12890-021-01522-6.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsFibrotic ILDInterobserver variationHistopathologic diagnosisUsual interstitial pneumonia/idiopathic pulmonary fibrosisFibrotic interstitial lung diseaseCurrent histopathologic criteriaUIP/IPFIdiopathic pulmonary fibrosisInterstitial lung diseaseDiagnosis of ILDExtent of inflammationPattern of fibrosisSignificant interobserver variationSpecific diagnostic featuresILD evaluationPulmonary fibrosisLung diseaseHistopathologic evaluationHistopathologic criteriaDiagnostic guidelinesTissue-based diagnosticsDiagnosisILDFibrosisInternet-based approaches
2018
Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805
Jilaveanu LB, Puligandla M, Weiss SA, Wang X, Zito C, Flaherty KT, Boeke M, Neumeister V, Camp RL, Adeniran A, Pins M, Manola J, DiPaola RS, Haas N, Kluger HM. Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805. Clinical Cancer Research 2018, 24: 217-223. PMID: 29066509, PMCID: PMC5904512, DOI: 10.1158/1078-0432.ccr-17-1555.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHigher microvessel densityDisease-free survivalRenal cell carcinomaHigh-risk RCC patientsImproved overall survivalOverall survivalMicrovessel densityRCC patientsAdjuvant therapy trialsClear cell histologyHigh-risk patientsBiomarkers of outcomeTumor microvessel densityLower microvessel densityAbsence of necrosisFuhrman grade 1Clin Cancer ResAdjuvant sunitinibProlonged OSCell histologyLymphovascular invasionSarcomatoid featuresMultivariable analysisTreatment armsEntire cohort
2015
Staphylococcal Purpura Fulminans
Honarpisheh H, Camp R, Lazova R. Staphylococcal Purpura Fulminans. American Journal Of Dermatopathology 2015, 37: 643-646. PMID: 25099358, DOI: 10.1097/dad.0000000000000175.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsPurpura fulminansPerivascular lymphocytic inflammationProgressive hemodynamic instabilityStaphylococcal purpura fulminansSolitary lung metastasisSmall cutaneous vesselsMultiorgan failureHemodynamic instabilityLymphocytic inflammationLung metastasesRectal adenocarcinomaSubepidermal bullaeCase reportEpidermal necrosisGeneralized eruptionAutopsy examinationSkin biopsiesBlack maculeCutaneous vesselsDay 3FulminansS. aureusStaphylococcus aureusAureusReportCharacterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens
Baine MK, Turcu G, Zito CR, Adeniran AJ, Camp RL, Chen L, Kluger HM, Jilaveanu LB. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget 2015, 6: 24990-25002. PMID: 26317902, PMCID: PMC4694809, DOI: 10.18632/oncotarget.4572.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsMeSH KeywordsAdolescentAdultAgedB7-H1 AntigenCarcinoma, Renal CellCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleFluorescent Antibody TechniqueForkhead Transcription FactorsHumansKidney NeoplasmsLymphocytes, Tumor-InfiltratingMaleMiddle AgedNeoplasm MetastasisTissue Array AnalysisYoung AdultConceptsRenal cell carcinomaT cell ratioMetastatic specimensPD-L1Cell carcinomaPD-1/PD-L1 blockadePD-1/PD-L1 statusPD-1/PD-L1 pathwayMetastatic renal cell carcinomaHigh PD-L1PD-L1 blockadeUnfavorable tumor characteristicsPD-L1 expressionPD-L1 statusPD-L1 pathwayT-cell contentPre-treatment tumorsLow CD8TIL subsetsCharacterization of tumorsTIL densitySuch patientsTumor characteristicsImmune activationPatient survival
2014
PAX-8 expression in renal tumours and distant sites: A useful marker of primary and metastatic renal cell carcinoma?
Barr ML, Jilaveanu LB, Camp RL, Adeniran AJ, Kluger HM, Shuch B. PAX-8 expression in renal tumours and distant sites: A useful marker of primary and metastatic renal cell carcinoma? Journal Of Clinical Pathology 2014, 68: 12. PMID: 25315900, PMCID: PMC4429054, DOI: 10.1136/jclinpath-2014-202259.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsRenal cell carcinomaPAX-8 expressionMetastatic renal cell carcinomaRenal tumorsMetastatic sitesCell carcinomaClear cell renal cell carcinomaPAX-8 stainingCell renal cell carcinomaPAX-8Distant sitesNormal renal tissueUseful diagnostic markerAdjacent normal kidneyHistological typePrimary tumorDistant tumorsLack of expressionRenal originImmunohistochemical stainsChromophobe tumorsClear cellsRenal tissueNormal kidneyTissue microarrayNY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma
Giesen E, Jilaveanu LB, Parisi F, Kluger Y, Camp RL, Kluger HM. NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma. Oncotarget 2014, 5: 5209-5217. PMID: 24970819, PMCID: PMC4170640, DOI: 10.18632/oncotarget.2101.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsNY-ESO-1 expressionNY-ESO-1Renal cell carcinomaCell carcinomaMetastatic sitesRenal tissueCancer-testis antigen NY-ESO-1Antigen NY-ESO-1Adjacent normal renal tissuesClear cell renal cell carcinomaRCC specimensMetastatic RCC specimensPapillary renal cell carcinomaCell renal cell carcinomaPotential immunotherapeutic targetAdoptive cell therapySubset of RCCTumor-specific antigensClear cell carcinomaNovel immune therapiesPrimary RCC specimensBenign renal tissueNormal renal tissueDifferent tumor sitesImmune therapyMicrovessel area as a predictor of sorafenib response in metastatic renal cell carcinoma
Aziz SA, Sznol JA, Albiges L, Zito C, Jilaveanu LB, Camp RL, Escudier B, Kluger HM. Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma. Cancer Cell International 2014, 14: 4. PMID: 24423208, PMCID: PMC3896780, DOI: 10.1186/1475-2867-14-4.Peer-Reviewed Original ResearchCitationsAltmetricConceptsRenal cell carcinomaMicrovessel areaHighest microvessel areaSorafenib responseCell carcinomaMetastatic renal cell carcinomaCD 34 stainingSmall primary tumorsProgression-free survivalAnti-angiogenic therapyVEGF-R2 inhibitorsAdditional patientsPatient selectionPredictive biomarkersPrimary tumorSorafenib sensitivityTumor specimensDrug AdministrationVEGF-R3VEGF-R1Immunofluorescence-based methodTumor samplesVEGF-R2C-kitPatients
2013
Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors
Aziz SA, Sznol JA, Adeniran A, Parisi F, Kluger Y, Camp RL, Kluger HM. Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors. BMC Clinical Pathology 2013, 13: 3. PMID: 23374878, PMCID: PMC3575219, DOI: 10.1186/1472-6890-13-3.Peer-Reviewed Original ResearchCitationsAltmetricConceptsRenal cell carcinoma tumorsMetastatic tumorsCarcinoma tumorsMetastatic specimensPredictive biomarker developmentFGF-R1Predictive biomarker testingRenal cell carcinomaTissue microarray blocksResultsNo significant differencesKi67-positive cellsMore Ki67-positive cellsSignificant differencesCell carcinomaBiomarker testingPDGF-RβMicroarray blocksPositive cellsQuantitative immunofluorescence methodVEGF-R3VEGF-R1Expression of targetsTumorsImmunofluorescence methodPrimary specimensVascularity of primary and metastatic renal cell carcinoma specimens
Aziz SA, Sznol J, Adeniran A, Colberg JW, Camp RL, Kluger HM. Vascularity of primary and metastatic renal cell carcinoma specimens. Journal Of Translational Medicine 2013, 11: 15. PMID: 23316728, PMCID: PMC3561185, DOI: 10.1186/1479-5876-11-15.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsRenal cell carcinomaMicrovessel areaMetastatic samplesCell carcinomaMetastatic sitesPrimary tumorMetastatic renal cell carcinomaRenal cell carcinoma tumorsClear cell tumorsClear cell carcinomaPredictive biomarker studiesAnti-angiogenic drugsAnti-angiogenic therapyTypes of tumorsHigh response ratePrimary nephrectomyHistologic subtypeCell tumorsDifferent histologyPapillary histologyCD 34Variable histologyClinical studiesClear cellsTumor vascularity
2012
c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Annals Of Oncology 2012, 24: 343-349. PMID: 23022995, PMCID: PMC3551486, DOI: 10.1093/annonc/mds463.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorCarcinoma, Renal CellCell Line, TumorCell ProliferationFemaleHepatocyte Growth FactorHumansIndolesKidney NeoplasmsMaleMiddle AgedPiperazinesPrognosisProto-Oncogene Proteins c-metPyrrolidinonesQuinolinesSulfonamidesTissue Array AnalysisConceptsRenal cell carcinomaClear cell renal cell carcinomaC-Met expressionCell renal cell carcinomaHigh c-Met expressionAdjacent normal renal tissuesNormal renal tissueARQ 197Cell carcinomaRenal tissueRCC tumorsTissue microarrayWorse disease-specific survivalC-MetClear cell RCC cell linesC-Met protein expressionCell linesPoor pathologic featuresCell subset analysisDisease-specific survivalPapillary renal cell carcinomaRange of malignanciesC-Met pathwayC-Met inhibitionPotential therapeutic target
Academic Achievements & Community Involvement
activity Breast Cancer Alliance
Peer Review Groups and Grant Study SectionsGrant ReviewerDetails2010 - Presenthonor Charles W. Bomfalk Prize (Medical Student Teaching)
Yale School of Medicine AwardDetails06/01/2013United Stateshonor Inspiring Yale, Invited Speaker
Yale University AwardDetails05/01/2013United States
News
News
- December 19, 2023
Physician Associate Class of 2023 Celebrated at Graduation Ceremony
- January 05, 2012
Students begin new semester with iPads
- December 01, 2011
Tablets an excellent prescription for School of Medicine’s students
- May 31, 2010
Breast Milk Protein Linked to Poorer Breast Cancer Survival in Younger Women
Get In Touch
Contacts
Email
Locations
Department of Pathology
Academic Office
Brady Memorial Laboratory
310 Cedar Street
New Haven, CT 06510
General Information
203.785.3624